Company Analysis
Sign in

Pharming Group N.V. (PHAR)

Nasdaq: PHAR · Pharmaceutical Preparations · Leiden, NL · filing with the SEC since 2020
Full chart Alerts Compare
Grade6.9
◀ Past 7.1● Present 7.0▶ Future 6.4
1 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart
The companyfiscal 2025, as filed
Revenue$376M+26.6%
Net income$2.5M+121.4%
Earnings per share$0.00+122.2%
Operating cash flow$54.7M+3147.8%
Cash$145M+164.5%
Debtn/a
Shareholders’ equity$277M+25.4%
Shares, diluted746.9M-4.9%
Return on equity0.9%
The recordfrom its filings
Filings in 202625
Newest filingNov 6 · 6-K
Annual reportApr 2, 2026
Quarterly reportn/a
Next report due20-F by Apr 30
Insider sales, 12 months$0.00
Insider buys, 12 months$0.00
Patents granted17
Filer categoryAccelerated filer
Left: the newest annual report, with the change on the year before. Right: counted from the company's own filings with the SEC.
Revenue and net income by fiscal yearRevenueNet income
19202122232425
As filed, in USD. Nothing here is a forecast.

News

An outside story is shown by its headline, its source and its link only. The SI reads the page when you ask it to break one down.
SI Assistanton PHAR · research, not advice